title: Albumin-bound paclitaxel in solid tumors: clinical development and future directions.
abstract: Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation of paclitaxel that was initially developed more than a decade ago to overcome toxicities associated with the solvents used in the formulation of standard paclitaxel and to potentially improve efficacy. Nab-paclitaxel has demonstrated an advantage over solvent-based paclitaxel by being able to deliver a higher dose of paclitaxel to tumors and decrease the incidence of serious toxicities, including severe allergic reactions. To date, nab-paclitaxel has been indicated for the treatment of three solid tumors in the USA. It was first approved for the treatment of metastatic breast cancer in 2005, followed by locally advanced or metastatic non-small-cell lung cancer in 2012, and most recently for metastatic pancreatic cancer in 2013. Nab-paclitaxel is also under investigation for the treatment of a number of other solid tumors. This review highlights key clinical efficacy and safety outcomes of nab-paclitaxel in the solid tumors for which it is currently indicated, discusses ongoing trials that may provide new data for the expansion of nab-paclitaxel's indications into other solid tumors, and provides a clinical perspective on the use of nab-paclitaxel in practice.
authors.affiliation: Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA.
authors.forename: Madappa N
authors.initials: MN
authors.lastname: Kundranda
authors.affiliation: Department of Medical Oncology, Cancer Treatment Centers of America, Goodyear, AZ, USA.
authors.forename: Jiaxin
authors.initials: J
authors.lastname: Niu
mesh_terms: D000068196:Albumin-Bound Paclitaxel / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D000418:Albumins / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D002626:Chemistry, Pharmaceutical / Q000639:trends; D004059:Diffusion of Innovation; D005544:Forecasting; D006801:Humans; D050997:Nanomedicine / Q000639:trends; D053758:Nanoparticles; D017239:Paclitaxel / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000639:trends
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel
keywords: breast; lung; melanoma; nab-paclitaxel; ovarian; pancreas